Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's
disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild …

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Throughout the body, lymphatic fluid movement supports critical functions including
clearance of excess fluid and metabolic waste. The glymphatic system is the analog of the …

Astrocytes play key roles in the regulation of brain energy metabolism, which has a major
impact on brain functions, including memory, neuroprotection, resistance to oxidative stress …

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by
extracellular amyloid β (Aβ) and intraneuronal tau protein aggregations. One risk factor for …

Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …

This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease
(AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 …

Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for
Alzheimer's disease (AD), have yielded significant insights into the pathogenic mechanism …